56 related articles for article (PubMed ID: 32175275)
21. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.
Olsson L; Castor A; Behrendtz M; Biloglav A; Forestier E; Paulsson K; Johansson B
Leukemia; 2014 Feb; 28(2):302-10. PubMed ID: 23823658
[TBL] [Abstract][Full Text] [Related]
22. Association of Piebaldism, multiple café-au-lait macules, and intertriginous freckling: clinical evidence of a common pathway between KIT and sprouty-related, ena/vasodilator-stimulated phosphoprotein homology-1 domain containing protein 1 (SPRED1).
Chiu YE; Dugan S; Basel D; Siegel DH
Pediatr Dermatol; 2013; 30(3):379-82. PubMed ID: 23016555
[TBL] [Abstract][Full Text] [Related]
23. SPRED proteins provide a NF-ty link to Ras suppression.
McClatchey AI; Cichowski K
Genes Dev; 2012 Jul; 26(14):1515-9. PubMed ID: 22802525
[TBL] [Abstract][Full Text] [Related]
24. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.
Stowe IB; Mercado EL; Stowe TR; Bell EL; Oses-Prieto JA; Hernández H; Burlingame AL; McCormick F
Genes Dev; 2012 Jul; 26(13):1421-6. PubMed ID: 22751498
[TBL] [Abstract][Full Text] [Related]
25. NF1 inactivation in adult acute myelogenous leukemia.
Parkin B; Ouillette P; Wang Y; Liu Y; Wright W; Roulston D; Purkayastha A; Dressel A; Karp J; Bockenstedt P; Al-Zoubi A; Talpaz M; Kujawski L; Liu Y; Shedden K; Shakhan S; Li C; Erba H; Malek SN
Clin Cancer Res; 2010 Aug; 16(16):4135-47. PubMed ID: 20505189
[TBL] [Abstract][Full Text] [Related]
26. Does SPRED1 contribute to leukemogenesis in juvenile myelomonocytic leukemia (JMML)?
Batz C; Hasle H; Bergsträsser E; van den Heuvel-Eibrink MM; Zecca M; Niemeyer CM; Flotho C;
Blood; 2010 Mar; 115(12):2557-8. PubMed ID: 20339110
[No Abstract] [Full Text] [Related]
27. SPRED 1 mutations in a neurofibromatosis clinic.
Muram-Zborovski TM; Stevenson DA; Viskochil DH; Dries DC; Wilson AR; Rong Mao
J Child Neurol; 2010 Oct; 25(10):1203-9. PubMed ID: 20179001
[TBL] [Abstract][Full Text] [Related]
28. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions.
Haferlach C; Dicker F; Kohlmann A; Schindela S; Weiss T; Kern W; Schnittger S; Haferlach T
Leukemia; 2010 May; 24(5):1065-9. PubMed ID: 20164853
[No Abstract] [Full Text] [Related]
29. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
Lauchle JO; Kim D; Le DT; Akagi K; Crone M; Krisman K; Warner K; Bonifas JM; Li Q; Coakley KM; Diaz-Flores E; Gorman M; Przybranowski S; Tran M; Kogan SC; Roose JP; Copeland NG; Jenkins NA; Parada L; Wolff L; Sebolt-Leopold J; Shannon K
Nature; 2009 Sep; 461(7262):411-4. PubMed ID: 19727076
[TBL] [Abstract][Full Text] [Related]
30. SPRED1 disorder and predisposition to leukemia in children.
Pasmant E; Ballerini P; Lapillonne H; Perot C; Vidaud D; Leverger G; Landman-Parker J
Blood; 2009 Jul; 114(5):1131. PubMed ID: 19643996
[No Abstract] [Full Text] [Related]
31. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype.
Spurlock G; Bennett E; Chuzhanova N; Thomas N; Jim HP; Side L; Davies S; Haan E; Kerr B; Huson SM; Upadhyaya M
J Med Genet; 2009 Jul; 46(7):431-7. PubMed ID: 19443465
[TBL] [Abstract][Full Text] [Related]
32. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations.
Li Z; Lu J; Sun M; Mi S; Zhang H; Luo RT; Chen P; Wang Y; Yan M; Qian Z; Neilly MB; Jin J; Zhang Y; Bohlander SK; Zhang DE; Larson RA; Le Beau MM; Thirman MJ; Golub TR; Rowley JD; Chen J
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15535-40. PubMed ID: 18832181
[TBL] [Abstract][Full Text] [Related]
33. miR-126 regulates angiogenic signaling and vascular integrity.
Fish JE; Santoro MM; Morton SU; Yu S; Yeh RF; Wythe JD; Ivey KN; Bruneau BG; Stainier DY; Srivastava D
Dev Cell; 2008 Aug; 15(2):272-84. PubMed ID: 18694566
[TBL] [Abstract][Full Text] [Related]
34. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis.
Wang S; Aurora AB; Johnson BA; Qi X; McAnally J; Hill JA; Richardson JA; Bassel-Duby R; Olson EN
Dev Cell; 2008 Aug; 15(2):261-71. PubMed ID: 18694565
[TBL] [Abstract][Full Text] [Related]
35. Deregulation of signaling pathways in acute myeloid leukemia.
Scholl C; Gilliland DG; Fröhling S
Semin Oncol; 2008 Aug; 35(4):336-45. PubMed ID: 18692684
[TBL] [Abstract][Full Text] [Related]
36. Clinical and molecular aspects of RAS related disorders.
Denayer E; de Ravel T; Legius E
J Med Genet; 2008 Nov; 45(11):695-703. PubMed ID: 18550698
[TBL] [Abstract][Full Text] [Related]
37. Getting a first clue about SPRED functions.
Bundschu K; Walter U; Schuh K
Bioessays; 2007 Sep; 29(9):897-907. PubMed ID: 17691106
[TBL] [Abstract][Full Text] [Related]
38. Spreds are essential for embryonic lymphangiogenesis by regulating vascular endothelial growth factor receptor 3 signaling.
Taniguchi K; Kohno R; Ayada T; Kato R; Ichiyama K; Morisada T; Oike Y; Yonemitsu Y; Maehara Y; Yoshimura A
Mol Cell Biol; 2007 Jun; 27(12):4541-50. PubMed ID: 17438136
[TBL] [Abstract][Full Text] [Related]
39. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
40. Implications of NRAS mutations in AML: a study of 2502 patients.
Bacher U; Haferlach T; Schoch C; Kern W; Schnittger S
Blood; 2006 May; 107(10):3847-53. PubMed ID: 16434492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
